




61P/1636 \$
RECEIVED
PATENT
Attorney Docket No. FJN-060
MAY 31 2001
(3998/63)
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Goto et al.
SERIAL NO.: 08/915,004 GROUP NO.: 1636
FILING DATE: February 20, 1996 EXAMINER: Schwartzman, R.
TITLE: NOVEL PROTEINS AND METHODS FOR PRODUCING THE
PROTEINS

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 C.F.R. 1.8

I hereby certify that this correspondence, and any document(s) referred to as enclosed herein, is/are being deposited with the United States Postal Service as first class mail, postage prepaid, in an envelope addressed to the Assistant Commissioner for Patents, Washington, DC 20231 on this 24th day of May, 2001.



Julie Westhaver

Assistant Commissioner for Patents
Washington, D.C. 20231

Sir:

Submitted herewith is/are:

Transmittal Form (1 pg.); Fee Transmittal (1 pg.); Copy of Fee Transmittal (1 pg.); Supplemental Information Disclosure Statement (2 pgs.); Form PTO 1449 (2 pgs.); References AF-AI, BE-BG and CK-CCB; and postcard.



TRANSMITTAL FORM

Application Serial Number	08/915,004
Filing Date	February 20, 1996
First Named Inventor	Goto et al.
Group Art Unit	1636
Examiner Name	Schwartzman, R.
Attorney Docket No.	FJN-060 (3999/63)
BATCH NO. (after allowance)	Not applicable
Patent No.	Not applicable
Issue Date	Not applicable

RECEIVED

MAY 31 2001

TECH CENTER 1600/2900

ENCLOSURES (check all that apply)

- | | | |
|--|---|--|
| <input checked="" type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Check Attached
<input checked="" type="checkbox"/> Copy of Fee Transmittal Form | <input type="checkbox"/> Copy of Notice to File Missing Parts of Application (PTO-1553) | <input type="checkbox"/> Notice of Appeal to Board of Patent Appeals and Interferences |
| <input type="checkbox"/> Amendment/Response
<input type="checkbox"/> Preliminary
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Letter to Official Draftsperson including Drawings [Total Sheets ____] | <input type="checkbox"/> Formal Drawing(s) | <input type="checkbox"/> Appeal Brief (in triplicate) |
| <input type="checkbox"/> Petition for Extension of Time | <input type="checkbox"/> Request For Continued Examination (RCE) Transmittal | <input type="checkbox"/> Status Inquiry |
| <input checked="" type="checkbox"/> Supplemental Information Disclosure Statement
<input checked="" type="checkbox"/> Form PTO-1449
<input checked="" type="checkbox"/> Copies of IDS Citations | <input type="checkbox"/> Power of Attorney (Revocation of Prior Powers) | <input checked="" type="checkbox"/> Return Receipt Postcard |
| <input type="checkbox"/> Certified Copy of Priority Document(s) | <input type="checkbox"/> Terminal Disclaimer | <input checked="" type="checkbox"/> Certificate of First Class Mailing under 37 C.F.R. 1.8 |
| <input type="checkbox"/> Sequence Listing submission
<input type="checkbox"/> Paper Copy/CD
<input type="checkbox"/> Computer Readable Copy
<input type="checkbox"/> Statement verifying identity of above | <input type="checkbox"/> Executed Declaration and Power of Attorney for Utility or Design Patent Application | <input type="checkbox"/> Certificate of Facsimile Transmission under 37 C.F.R. 1.8 |
| | <input type="checkbox"/> Small Entity Statement | <input type="checkbox"/> Additional Enclosure(s) (please identify below) |
| | <input type="checkbox"/> CD(s) for large table or computer program | |
| | <input type="checkbox"/> Amendment After Allowance | |
| | <input type="checkbox"/> Request for Certificate of Correction
<input type="checkbox"/> Certificate of Correction (in duplicate) | |

CORRESPONDENCE ADDRESS


Direct all correspondence to: Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Date: May 24, 2001
Reg. No. 44,244
Tel. No.: (617) 248-7044
Fax No.: (617) 248-7100

Ronda P. Moore, D.V.M.
Ronda P. Moore, D.V.M.
Attorney for Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower
125 High Street
Boston, MA 02110



FEE TRANSMITTAL

FEE 2001

Complete if Known

Application Serial Number 08/915,004
Filing Date February 20, 1996
First Named Inventor Goto et al.
Group Art Unit 1636
Examiner Name Schwartzman, R.
Attorney Docket No. FJN-060 (3999/63)

RECEIVED

MAY 31 2001

TECH CENTER 1600/2900

METHOD OF PAYMENT

1. ☐ Payment Enclosed:
☐ Check ☐ Money Order ☐ Other
2. ☒ The Commissioner is hereby authorized to credit or charge any fee indicated below for this submission to Deposit Account No. 20-0531.
☒ Required Fees (copy of this sheet enclosed).
☒ Additional fee required under 37 CFR 1.16 and 1.17.
☒ Overpayment Credit.
3. ☐ Applicant claims small entity status.

FEE CALCULATION

1. FILING FEE

Large Entity Fee (\$)	Fee Description	Fee Paid
710	Utility filing fee	
320	Design filing fee	
150	Provisional filing fee	

	Number Filed	Number Extra	Rate	Amount
Total Claims	- 20 =		x \$ 18.00 =	

Independent Claims	- 3 =		x \$ 80.00 =	
-----------------------	-------	--	--------------	--

☐ Multiple Dependent Claim(s), if any \$270.00 =

TOTAL:
SMALL ENTITY DISCOUNT:
SUBTOTAL (1) (\$) 0

2. AMENDMENT CLAIM FEES

Claims Remaining After Amend.	Highest No. Previously Paid For	Present Extra	Rate	Fee Paid
Total	-	=	x \$ 18.00 =	
Indep.	-	=	x \$ 80.00 =	
<input type="checkbox"/> First Presentation of Multiple Dep. Claim			+ \$270.00 =	

TOTAL: (\$)
SMALL ENTITY DISCOUNT: (\$)
SUBTOTAL (2) (\$) 0

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee (\$)	Small Entity Fee (\$)	Fee Description	Fee Paid
130	65	Surcharge - late filing fee or oath	
50	25	Surcharge - late provisional filing fee or cover sheet	
130	130	Non-English specification	
2,520	2,520	For filing a request for reexamination	
110	55	Extension for reply within first month	
390	195	Extension for reply within second month	
890	445	Extension for reply within third month	
1,390	695	Extension for reply within fourth month	
1,890	945	Extension for reply within fifth month	
310	155	Notice of Appeal	
310	155	Filing a brief in support of an appeal	
270	135	Request for oral hearing	
130	130	Petitions to the Commissioner	
50	50	Petitions related to provisional applications	
180	180	Submission of Information Disclosure Statement	180.00
710	355	Filing a submission after final rejection (37 CFR 1.129(a))	
710	355	For each additional invention to be examined (37 CFR 1.129(b))	

Other fee (Specify)

Other fee (Specify)

SUBTOTAL (3) (\$) 180.00

SUBTOTAL (1) 0
SUBTOTAL (2) 0
SUBTOTAL (3) 180.00

TOTAL (\$) 180.00

CORRESPONDENCE ADDRESS

Direct all correspondence to:

Patent Administrator
Testa, Hurwitz & Thibault, LLP
High Street Tower-125 High Street
Boston, MA 02110
Tel. No.: (617) 248-7000
Fax No.: (617) 248-7100

SIGNATURE BLOCK

Respectfully submitted,

Ronda P. Moore, D.V.M.
Ronda P. Moore, D.V.M.
Attorney for the Applicants
Testa, Hurwitz & Thibault, LLP
High Street Tower-125 High Street
Boston, MA 02110

Date: May 24, 2001
Reg. No.: 44,244
Tel. No.: (617) 248-7044
Fax No.: (617) 248-7100



RECEIVED

MAY 31 2001

Attorney Docket No. FJN-060
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Goto et al.
SERIAL NO.: 08/915,004 GROUP NO.: 1636
FILING DATE: February 20, 1996 EXAMINER: Schwartzman, R.
TITLE: NOVEL PROTEINS AND METHODS FOR PRODUCING THE PROTEINS

Assistant Commissioner for Patents
Washington, D.C. 20231

05/30/2001 TGEDAHU1 00000015 200531 08915004
01 FC:126 180.00 CH

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with the provisions of 37 C.F.R. 1.97 and 1.98, Applicants hereby make of record the patents and publications listed on the accompanying Form PTO-1449, and other information contained herein, for consideration by the Examiner in connection with the examination of the above-identified patent application. Copies of the patents and publications are enclosed.

Applicants respectfully submit that under the procedural status of the instant application, Applicants are entitled to submit this statement with fees. The Patent Office is hereby authorized to charge \$180.00 to deposit account no. 20-0531.

REMARKS

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed (CHECK ONE):

- ☐ (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office action** on the merits, or before the mailing of a **first Office action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- ☐ (2) after the period defined in (1) but before the mailing date of a **final action** or a **notice of allowance** under 37 C.F.R. 1.311, and
- ☐ the requisite Statement is below, **OR**

- ☐ the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00**, is included herein, or
- ☐ (3) after the mailing date of a **final action** or **notice of allowance** but before the payment of the **issue fee**, **AND**
- ☐ the requisite Statement is below, **AND**
- ☐ the requisite petition fee under 37 C.F.R. 1.17(p), namely **\$180.00** is included herein.

It is respectfully requested that each of the patents and publications listed on the attached Form PTO-1449, and other information contained herein, be made of record in this application.

STATEMENT

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that [check the appropriate space only if either (2) or (3) is checked on the previous page and the Statement is required]:

- ☐ 1. Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- ☐ 2. No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,

Date: May 24, 2001
Reg. No. 44,244

Tel. No.: (617) 248-7044
Fax No.: (617) 248-7100

2096411

Ronda P. Moore, D.V.M.
Ronda P. Moore, D.V.M.
Attorney for Applicants
Testa, Hurwitz, & Thibeault, LLP
High Street Tower
125 High Street
Boston, Massachusetts 02110



RECEIVED

MAY 31 2001

TECH CENTER 9800/2900

FORM PTO - 1449				ATTORNEY DOCKET NO.: FJN-060					
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT				APPLICANT(S): Goto et al.					
				SERIAL NO.: 08/915,004					
				FILING DATE: February 20, 1996 GROUP:					
U.S. PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	AF	4,179,337	12/18/79	Davis et al.					
	AG	5,447,851	9/5/95	Beutler et al.					
	AH	5,843,678	12/1/98	Boyle					
	AI	6,017,729	1/25/00	Anderson et al.					
FOREIGN PATENT DOCUMENTS									
EXAM. INIT.		DOCUMENT NUMBER	DATE	COUNTRY CODE	CLASS	SUB CLASS	FILING DATE	ABSTRACT ONLY	ENGLISH LANG (Y/N)
	BE	EP 0816 380 A1	01/07/98	WO					Y
	BF	330,400	05/28/99	NZ					Y
	BG	98 07840 A1	8/19/97	WO					N
OTHER ART, JOURNAL ARTICLES, ETC.									
EXAM. INIT.	OTHER DOCUMENTS: (Including Author, Title, Date, Relevant Pages, Place of Publication)								
	CK	Adams, M.D. et al., "Complementary DNA Sequencing: Expressed Sequence Tags and Human Genome Project", <u>Science</u> , vol. 252, 21 June 1991, pp. 1651-1656.							
	CL	Anderson et al., "A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function", <u>Nature</u> , Vol. 390, November 13, 1997, pp. 175-179.							
	CM	Chenu et al., "Transforming growth factor β inhibits formation of osteoclast-like cells in long-term human marrow cells," <u>Proceed. of the National Acad. of Sciences of USA</u> , vol. 85, August 1998, pgs. 5683-5687.							
	CN	Database on GenEmbl, Anderson et al. Accession NO. AF019048 "Mus musculus receptor activator of nuclear factor kappa B ligand RANKL)							
	CO	George et al., <u>Macromolecular Sequencing and Synthesis</u> , New York, 1998, pg. 127-149.							
	CP	Goodwin et al., "Molecular cloning and expression of the type 1 and type 2 receptors for tumor necrosis factor," Database EMROD, EMBL Databases, Accession Number: M59378, June 28, 1991.							
EXAMINER					DATE CONSIDERED				

MAY 29 2001

RECEIVED
SHEET 2 OF 2

MAY 31 2001

TECH CENTER 1600/2900

FORM PTO - 1449

ATTORNEY DOCKET NO.: FJN-960

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

APPLICANT(S): Goto et al.

SERIAL NO.: 08/915,004

FILING DATE: February 20, 1996 GROUP:

CQ	Gowen et al., "Preferential Inhibition of Cytokine-Stimulated Bone Resorption by Recombinant Interferon Gamma," <u>Journal of Bone and Mineral Research</u> , vol. 1, number 5, 1986, pgs. 469-474.
CR	Hattersley et al., "Human Macrophage Colony-Stimulating Factor Inhibits Bone Resorption by Osteoclasts Disaggregated From Rat Bone," <u>Journal of Cellular Physiology</u> , vol. 137, number 1, October 1998, pgs. 199-203.
CS	International Search Report for PCT/JP98/01728
CT	Kaji et al., "Insulin-like growth factor-I mediates osteoclast-like cell formation stimulated by parathyroid hormone", <u>Journal of Cellular Physiology</u> , Vol. 172, No. 1, July 10, 1997, pp. 55-62.
CU	Kasono et al., "Inhibitory effect of interleukin-4 on osteoclast-like cell formation in mouse bone marrow culture," <u>Bone and Mineral</u> , vol. 21, 1993, pgs. 179-188.
CV	Kukita et al., "Osteoinductive factor inhibits formation of human osteoclast-like cells", <u>Proc. Natl. Acad. Sci. USA</u> , vol. 87, 29 January 1990, pp. 3023-3026.
CW	Lewis et al., "Cloning and expression of cDNAs for two distinct murine tumor necrosis factor receptors demonstrate one receptor is species specific", <u>Proc. Natl. Aca. Sci. USA</u> , vol. 88, 1991, pp. 2830-2834.
CX	Rieger et al., <u>Glossary of Genetics and Cytogenetics</u> , Springer-Verlag, Berlin Heidelberg New York, 1976, pg. 17.
CY	Takada et al., "A simple method to assess osteoclast-mediated bone resorption using unfractionated bone cells," <u>Bone and Mineral</u> , vol. 17, 1992, pgs. 347-359.
CZ	Watanabe et al., "Interleukin-4 as a Potent Inhibitor of Bone Resorption," <u>Biochem. and Biophys. Research Comm.</u> , vol. 172, number 3, 1990, November 1990, pgs. 1035-1041.
CCA	Wong et al., "TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cell", <u>J.Biol. Chem.</u> , Vol. 272, No. 40, October 28, 1997, pp. 24727-25408.
CCB	Yoneda, Toshiyuki, et al., "Sumarin Suppresses Hypercalcemia and Osteoclastic Bone Resorption in Nude Mice Bearing a Human Squamous Cancer", vol. 55, 1 May 1995, pp. 1989-1993, <u>Cancer Research</u> .
EXAMINER	
DATE CONSIDERED	

2096397